Evoke Pharma (NASDAQ:EVOK) has been assigned a $9.00 price objective by analysts at HC Wainwright in a report issued on Wednesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 237.08% from the company’s previous close.

Several other equities research analysts also recently issued reports on EVOK. Zacks Investment Research downgraded shares of Evoke Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. ValuEngine raised shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Seaport Global Securities reiterated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a research note on Friday, October 6th. Northland Securities reiterated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a research note on Wednesday, October 18th. Finally, FBR & Co reiterated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a research note on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. Evoke Pharma has an average rating of “Buy” and a consensus target price of $9.00.

Shares of Evoke Pharma (NASDAQ EVOK) traded up $0.08 during trading on Wednesday, reaching $2.67. 102,800 shares of the company’s stock were exchanged, compared to its average volume of 412,050. Evoke Pharma has a 12 month low of $1.42 and a 12 month high of $4.55.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.13). During the same period last year, the firm earned ($0.29) EPS. equities research analysts anticipate that Evoke Pharma will post -0.75 EPS for the current year.

Institutional investors have recently modified their holdings of the business. State Treasurer State of Michigan boosted its stake in shares of Evoke Pharma by 37.0% in the 2nd quarter. State Treasurer State of Michigan now owns 400,000 shares of the specialty pharmaceutical company’s stock valued at $1,024,000 after purchasing an additional 108,034 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Evoke Pharma by 15.1% in the 2nd quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after purchasing an additional 68,544 shares during the last quarter. Finally, Sphera Funds Management LTD. boosted its stake in shares of Evoke Pharma by 14.2% in the 3rd quarter. Sphera Funds Management LTD. now owns 571,022 shares of the specialty pharmaceutical company’s stock valued at $1,907,000 after purchasing an additional 71,022 shares during the last quarter. 13.64% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Evoke Pharma (EVOK) Given a $9.00 Price Target by HC Wainwright Analysts” was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/12/01/evoke-pharma-evok-given-a-9-00-price-target-by-hc-wainwright-analysts.html.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.